EDGAR·FLOW

Black Diamond Therapeutics, Inc. — Form 8-K

Filed November 10, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 72/100
What the filing says
Black Diamond reported updated Phase 2 results for silevertinib in EGFR-NCM NSCLC: 86% CNS-ORR in 16 patients with untreated brain metastases (7 evaluable by RANO-BM), 15.0-month mPFS in 43-patient ITT cohort, 60% ORR. FDA End-of-Phase 2 meeting (Oct 1, 2026) supported pivotal Phase 3 development targeting ~300 patients, planned Q2 2027 initiation, with potential accelerated approval on CNS-ORR and full approval on PFS. Company has $102.0M cash (down from $128.7M at Dec 31, 2025), runway to H2 2028.
Why this rating

Positive Phase 2 data with FDA regulatory clarity de-risks pivotal program; but cash burn ($8.3M/Q) and $102M runway (~15 months) require near-term financing. Silevertinib is core asset; Phase 3 success critical but not assured. Meaningful for $113.8M company.

Tradability signal
NO TRADE

No trade: the filing reads positive but the market is selling it (-10.4% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$2.02 ▲ 10.81%
at our read · unknown
$1.82
+10 min · unknown
$1.76 ▼ 3.46%
+30 min · unknown
$1.82 ▲ 0.11%
+1 hr · unknown
$1.72 ▼ 5.92%
+4 hrs · unknown
$1.60 ▼ 12.23%

The stock had already moved -9.75% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ BDTX · stock on Yahoo Finance ↗

See more from November 10, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.